NCT02658890 2023-08-28An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadBristol-Myers SquibbPhase 1/2 Completed627 enrolled 59 charts